Effects of Oseltamivir Treatment in the Biological Behaviour and Glycosylation Pattern of Mammary Tumour Cell Lines by Ana Lídia Alves dos Santos
  
 
ANA LÍDIA ALVES DOS SANTOS 
 
 
 
 
 
 
EFFECTS OF OSELTAMIVIR TREATMENT IN THE BIOLOGICAL 
BEHAVIOUR AND GLYCOSYLATION PATTERN OF MAMMARY 
TUMOUR CELL LINES 
 
 
 
 
 
 
 
 
 
 
 
Dissertação de candidatura ao grau de 
Mestre em Oncologia - Especialização em 
Oncologia Molecular submetida ao 
Instituto de Ciências Biomédicas Abel 
Salazar da Universidade do Porto. 
 
Orientadora - Professora Doutora Joana 
Tavares de Oliveira 
Categoria - Professora Auxiliar 
Afiliação - Faculdade de Medicina 
Veterinária da Universidade Lusófona de 
Humanidades e Tecnologias. 
 
Co-orientadora – Professora Doutora 
Maria de Fátima Moutinho Gärtner 
Categoria - Professora catedrática 
Afiliação - Instituto de Ciências 
Biomédicas Abel Salazar Universidade do 
Porto. 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
ACKNOWLEDGMENTS 
 
I would like to sincerely thank to: 
 
 
 
 
Professor Joana de Oliveira and Professor Fátima Gärtner, for having accepted me and 
for all the support during this past year. 
 
 
Professor Manuel Sobrinho-Simões, head of IPATIMUP, for hosting me for my thesis 
work. 
 
 
Professor Celso Reis, for having accepted me in the Glycobiology in Cancer group. 
 
 
To all the members of Glycobiology in Cancer and Differentiation in Cancer, two nice 
groups of which I’m grateful to be part of. Particularly to Catarina, for all the strength and 
support she gave me. 
 
 
To all of my friends, for making me know that friends are the family we choose. 
 
 
Finally, the most important and deepest thank. To my parents, my brother and my 
godmother, thank you for making of me all that I am. 
 
 
 
 
 
 
 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
ABREVIATTIONS 
 
 
IARC, International Agency for Research on Cancer 
TMC, tumores mamários de cadela 
TMMC, tumores mamários malignos de cadela 
CMT, canine mammary tumours 
CMMT, canine mammary malignant tumour 
TACA, tumour-associated carbohydrate antigens 
T antigen, Thomsen-Friedenreich antigen 
sT antigen, sialylated form of T antigen / sialylated T antigen 
Tn antigen, Thomsen-nouvelle antigen 
sTn antigen, sialylated form of Tn antigen / sialylated Tn antigen 
sLex antigen, sialyl-Lewis antigen x 
sLea antigen, sialyl-Lewis antigen a 
Lea antigen, Lewis antigen a 
Leb antigen, Lewis antigen b 
Lex antigen, Lewis antigen x 
Ley antigen, Lewis antigen y 
MUC1, Mucin-1 
ST6Gal-I, Beta-galactoside alpha-2,6-sialyltransferase 1 
Mgat5, Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A 
SNA, Sambucus nigra agglutinin 
MAL / MAL-I / MAA / MAA-1, Maackia amurensis leukoagglutinin 
MAH / MAL-II / MAA / MAA-2, Maackia amurensis hemagglutinin 
Neu1, neuraminidase/sialidase 1 
Neu2, neuraminidase/sialidase 2 
Neu3, neuraminidase/sialidase 3 
Neu4, neuraminidase/sialidase 4 
EGFR, epidermal growth factor receptor 
EGF, epidermal growth factor 
GM3, monosialoganglioside  
GD3, trisialoganglioside 
LPS, lipopolysaccharide 
PTNM, Pathological Tumour-Node Metastasis 
IDC, invasive ductal carcinomas 
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RESUMO 
 
Os tumores mamários de cadela (TMC) partilham muitas semelhanças com o 
cancro de mama na mulher, no entanto, apresentam uma incidência 3 vezes maior, e um 
tempo de doença mais curto. Deste modo, os TMC constituem um excelente modelo 
espontâneo da carcinogénese mamária. Relativamente à mulher, o cancro de mama é o 
tipo de cancro mais comum, no entanto, a taxa de mortalidade é baixa. Por ano, em cada 
100.000 mulheres cerca de 6 a 19 morrem por cancro de mama. Este facto deve-se à 
melhoria dos diagnósticos e terapêutica. Assim sendo, o tumor mamário maligno de 
cadela, considerado um excelente modelo espontâneo da carcinogénese mamária, 
poderá melhorar o conhecimento sobre o processo metastático em humanos e trazer 
vantagens no que diz respeito ao tratamento tanto na cadela como na mulher. 
Os glicoconjugados na superfície celular desempenham papéis importantes numa 
variedade de funções biológicas, tais como interação célula-a-célula e célula-substrato, 
adesão de bactérias, organização da membrana e imunogenicidade. Alterações à 
estrutura dos glicoconjugados desempenham um papel relevante durante o processo de 
carcinogénese. Geralmente estas alterações estão associadas à expressão de antigénios 
característicos de tumor em glicoproteínas e glicolípidos que decoram a superfície 
celular. Por exemplo, um aumento em estruturas sialiladas é frequentemente observado 
em carcinomas e está associado ao estadio da doença, capacidade de invasão, 
metástases e mau prognóstico. 
Devido à função preponderante na tumorigénese mamária de várias 
glicoproteínas, e dos glicanos que estas transportam, o presente estudo teve como 
objetivo investigar o papel do oseltamivir como inibidor de sialidases a fim de 
compreender o seu modo de ação em glicoproteínas durante a progressão do tumor 
mamário, recorrendo a um modelo celular de TMC. Para isso, procedeu-se à avaliação 
da viabilidade celular, da capacidade de proliferação, migração e invasão, e a possível 
alteração no perfil de glicoconjugados em duas linhas celulares CMA07 e CMT-U27, após 
inibição das sialidases por tratamento com oseltamivir. 
Os resultados mostraram que o oseltamivir desempenha um papel importante no 
comportamento biológico e leva à alteração do padrão de glicosilação de glicoconjugados 
nas linhas celulares de TMC. A inibição das sialidases demonstrou a sua importante 
função durante a progressão do tumor mamário tendo-se verificado um aumento na 
capacidade de invasão e também na migração das células após tratamento. Além disso, 
e tendo em consideração o padrão de glicosilação, células malignas CMT-U27 tratadas 
com oseltamivir apresentam um aumento em estruturas sialiladas, com uma 
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concomitante diminuição de ligandos de galectina-3. Essas observações apontam para 
um papel dinâmico e importante das sialidases em TMMC (tumores mamários malignos 
de cadela). Assim, os resultados deste estudo demonstram o papel importante da 
expressão e atividade de sialidases na capacidade invasiva de células de carcinoma 
mamário possivelmente graças à sua capacidade de remoção de ácidos siálicos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
ABSTRACT 
 
Canine mammary tumours (CMT) are considered an excellent spontaneous model 
of mammary carcinogenesis because they share many similarities with human breast 
cancer. However, CMT presents a 3 times increased incidence than that of humans, and 
a shorter disease time course. Regarding women, breast cancer is the most common type 
of cancer. In women, breast cancer mortality rate is much lower than incidence rate. CMT 
can be used to improve our understanding about the metastatic process in humans 
bringing advantages for cancer treatment both for female dog and women. 
Cell surface glycoconjugates play important roles in a variety of biological 
functions, such as cell-cell and cell-substrate interactions, membrane organization and 
cell immunogenicity. Thus, alterations in glycosylation are considered a hallmark during 
carcinogenesis, and these alterations usually lead to the expression of tumour-associated 
carbohydrate antigens on glycoproteins and glycolipids decorating cell surfaces. 
Increased sialylation is commonly observed in carcinoma cells and is associated with 
tumour grade, invasion, metastasis and poor prognosis of patients. Sialic acids removal 
from carbohydrate chains of glycolipids and glycoproteins by sialidases can affect the 
conformation of glycoproteins. 
Due to the preponderant function of several glycoproteins and their carried glycans 
in mammary tumourigenesis, the present study aimed to investigate the role of 
oseltamivir, a sialidase inhibitor, in order to understand how sialidases are putatively able 
to act on glycoproteins during mammary tumour progression using CMT derived cell lines. 
To achieve this, we assessed cellular viability, proliferation capacity, migration and 
invasion in two cell lines CMA07 and CMT-U27, and evaluated a possible alteration in the 
glycoprofile of glycoconjugates in CMT cell lines upon sialidase inhibition. 
The results showed that oseltamivir plays an important role in the biological 
behaviour of cancer cells and leads to alterations in the glycosylation pattern of 
glycoconjugates in CMT cell lines. Sialidase inhibition results highlight their important role 
during mammary tumour progression since we found an increase in invasion capacity and 
also in migration of cells upon treatment. Moreover, regarding the glycosylation pattern, 
highly malignant CMT-U27 cells treated with oseltamivir, showed an increase in sialylated 
structures, with concomitant decrease in galectin-3-ligands. These observations point to 
an important dynamic role of sialidases expression in mammary tumours. Overall, these 
results imply an important role of sialidases expression and activity in the invasive 
capacity of mammary cancer cells, possibly due to their ability to remove sialic acid. 
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Canine mammary tumours 
Canine mammary tumours (CMT) are the second most common type of canine 
neoplasia (25-50% of all diagnosed cases) (Moulton 1990). CMT are the most frequent 
type of female dog tumours being up to 53% of all tumours (Rutteman 2001). CMT are 
mainly diagnosed in elderly females, being relatively rare before 2 to 4 years of age and 
presenting a higher incidence between 10 and 11 years of age (Schneider 1970); 
(Johnston 1993). 
Mammary tumour initiation and progression are influenced by similar factors in 
both human and canine cancers, including age, nutrition, gender, reproductive status and 
environmental exposure (Lana 2007). In addition, several major aspects of metastasis-
associated gene expression are also similar between human and canine mammary 
tumours (Rutteman 2001, Lindblad-Toh et al., 2005). However, the incidence of mammary 
tumours is 3 times higher in female dogs than in women and the time course of the 
disease much shorter, approximately 2 years (Sorenmo 2003). As such, it is an excellent 
comparative model to understand various aspects of not only breast carcinogenesis but 
also and perhaps most importantly metastasis in women. Also, the relatively rapid cancer 
progression rates, compared with those in humans, provide the opportunity to observe 
therapeutic effects in a shorter period of time than trials conducted in human patients 
(Leahy et al., 2006). In addition, a great advantage of spontaneous tumours is the cross-
sectional value of genetic diversity background provided, which similar to that seen in 
human populations as opposed to experimental animal studies (Lindblad-Toh et al., 
2005). 
Thus, the pet dog might support the transition between mouse models and human 
patients (Paoloni et al., 2008). 
Human breast cancer 
Cancer is a major public health problem in the world. Breast cancer is one of the 
most prevalent cancers (Figure 1), and metastatic breast cancer accounts for the highest 
number of cancer-related deaths among women worldwide. In 2008, breast cancer 
incidence was higher in Western Europe, Australia/New Zealand, Northern Europe and 
Northern America (Ferlay et al., 2010). 
Currently, about 1 in 3 women in the United States develop cancer in her lifetime 
(Siegel et al., 2012), and it is estimated that there are nearly 3 million people with a 
invasive breast cancer history. Overall, 60% of these breast cancer cases are diagnosed 
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in an early stage (Howlader et al., 2011). Despite more than 1.38 million of new cases 
diagnosed each year and over 458.000 deaths recorded, our knowledge on systemic 
cancer cell dissemination is scarce (Ferlay et al., 2010). 
 
 
 
 
Figure1. Incidence and mortality rates of the different types of cancer affecting women worldwide, in 
2008. Breast cancer presented both the higher incidence and mortality rates in women worldwide. (Data from 
GLOBOCAN - IARC). 
Glycosylation 
Glycosylation is one of the most important modifications in proteins and lipids, 
originating several glycoconjugates: glycoproteins, glycosaminoglycans, proteoglycans 
and glycolipids. Vital interactions between cells and the microenvironment surrounding 
them are mediated by the glycocalyx, a glycan layer which covers the external cell surface 
(Malagolini et al., 2009). In addition, cellular glycosylation has also been shown to 
coordinate key biological processes including cell-cell communication, signal transduction, 
protein folding and stability (Varki 1993); (Dwek 1995); (Wells et al., 2001). 
In proteins, oligosaccharide chains can be attached to the peptide backbone via 
two chief types of linkages: (a) aglycosidic bond of N-acetylgalactosamine (GalNAc) to the 
hydroxyl group of threonine or serine on the polypeptide chain, the O-linked glycans which 
are predominantly membrane bound or secreted on proteins; (b) a glycosidic bond of N-
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acetylglucosamine (GlcNAc) to asparagine occurring on the consensus sequence Asn-X-
Ser/Thr of a protein chain, the to N-linked glycan chains (Opdenakker et al., 1993). 
Mammalian cells have a specific enzymatic machinery that includes glycosyltransferases 
and glycosidases, which is required for biosynthesis of these diverse glycan structures, in 
the endoplasmic reticulum and Golgi apparatus. The glycan structures found are further 
dependent on the cell type, developmental stage and cell differentiation, and are 
fundamentally altered in many pathologic states, including cancer (Opdenakker et al., 
1993). In cancer, glycosylation changes have been often associated to a deregulation of 
glycosyltransferase genes expression. Glycosyltransferase genes ST6Gal-I (N-
acetyllactosaminide α-2,6 sialyltransferase) and Mgat5 (Alpha-1,6-mannosylglycoprotein 
6-beta-N-acetylglucosaminyltransferase A) are,  for instance, regulated by oncogenes. 
However more recently, a role played by glycosidases such as sialidases in neoplasia has 
been increasingly recognized. 
Sialidases 
Sialidases are enzymes that exist widely in vertebrates and in a variety of 
microorganisms (viruses, bacteria, fungi, mycoplasma and protozoa) with evidence of 
great importance in various cellular functions (Schengrund et al., 1976); (Corfield et al., 
1981); (Corfield et al., 1982); (Saito et al., 1995). The enzymes also are present in a large 
variety of cells and tissues from mammalians (Carubelli et al., 1962). 
Four types of mammalian sialidases have been identified and characterized to 
date, and designated as Neu1, Neu2, Neu3 and Neu4. The first three were classically 
described to localize predominantly in the lysosomes, cytosol and plasma membranes 
(Miyagi et al., 1999) respectively, and Neu4, the most recently identified sialidase, is often 
found in lysosomes, mitochondria and the endoplasmic reticulum (Roggentin et al., 1989); 
(Saito et al., 1996). However, their subcellular localization can vary with particular cell 
stimuli. Neu1, Neu2 and Neu4 show mobilization to the cell surface in certanin conditions 
(Saito et al., 1996). The overall amino acid identity between the four sialidases is variable. 
Amino acid identity between Neu1 and the other sialidases is relatively low (19-24%), 
while Neu2, Neu3 and Neu4 present a higher 34-40% homology between each other. 
Regarding comparative expression levels of sialidases in different human tissues, Neu1 
usually presents the highest expression, on the opposite to Neu2, which presents 
extremely low expression levels (Yamaguchi et al., 2006). Sialidases have been 
implicated in lysosomal catabolism, and regulation of important cellular functions such as 
cell differentiation, cell growth and apoptosis (Thomas et al., 2001); (Miyagi et al., 2012). 
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The function of each sialidase is linked to its glycan specificity. Neu1 hydrolyzes 
glycoproteins and in vitro sialidase activity assays showed that Neu1 reacts with high 
specificity with oligosaccharides and glycopeptides (Saito et al., 1996). Moereover, it acts 
preferentially on oligosaccharide substrates with α2-3 sialyl linkage when comparing to 
those with α2-6 (Miyagi et al., 1984). Neu2 hydrolyzes native glycoproteins, 
oligosaccharides and also gangliosides (Miyagi et al., 1985). It acts in the cytosol 
preferentially on α2-8 sialyl linkages (Miyagi et al., 1985). Despite  glycoconjugates being 
not usually present in the cytosol (Ishizuka et al., 2008),  glycoproteins, oligosaccharides, 
gangliosides,  glycosidases and lectins have been reported to occur in cytosol (Funakoshi 
et al., 2009). Neu3, hydrolyzes specifically gangliosides with α2-3 (GM3, 
monosialoganglioside) and α2-8 (GD3, trisialoganglioside) and α2-6 linkages (synthetic 
GM3) (Hata et al., 1998). The murine enzyme acts on oligosaccharides and glycoproteins 
to a certain extent (Li et al., 2001). Neu4 it is the only sialidase known toacts on mucins 
with high efficiency (Shiozaki et al., 2011). NEU4 was found to in vitro hydrolyze sLea and 
sLex antigens and to decrease their cell surface levels much more effectively than other 
sialidases (Shiozaki et al., 2011). 
Sialidases and cancer 
It is known that alterations in glycosylation such as increased sialylation are a 
common feature of malignancy (Reis et al., 2010). Sialic acids are terminal acidic 
monosaccharides usually found in the terminal position of the carbohydrate groups of 
glycoproteins and glycolipids. Their removal catalysed by sialidases may affect the 
conformation of glycoproteins, and therefore contribute to recognition or masking of 
biological sites in molecules and cells (Yogeeswaran et al., 1981); (Dennis et al., 1987); 
(Schauer 2000). This may influence the malignant phenotype of cancer cells, including the 
metastatic potential and invasiveness (Hakomori 2002). Sialidases have been found to be 
differentially expressed in several types of cancer, specifically in highly metastatic cells 
(Miyagi et al., 2008). 
NEU1 expression is decreased in several types of cancer. Its expression levels 
present an inverse relation with the metastatic cancer capacity. In different clones of 
mouse colon adenocarcinoma cells, lower expression of NEU1 sialidase where seen in 
those with higher metastatic rates when comparing to less invasive ones. There were 
concomitantly higher levels of sialyl Lex and GM3 in these cells (Sawada et al., 2002). 
Furthermore, transfection of Neu1 sialidase into mouse melanoma cells resulted in 
suppression of experimental pulmonary metastasis due to concomitant reduction in 
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anchorage-independent growth and increased sensitivity to apoptosis (Kato et al., 2001). 
Overexpression of human NEU1 with the PPCA gene resulted in similar alterations in 
human colonic adenocarcinoma cells with suppressed cell migration and invasion being 
shown. On the other hand, Neu1 knockdown resulted in the opposed effect (Galjart et al., 
1988); (D'Azzo et al., 1982). NEU1-expressing cells present reduced in vivo liver 
metastatic potential in mice (Uemura et al., 2009). 
Regarding NEU2, its up-regulation also affects cancer cell behaviour. Transfection 
of rat gene Neu2 into highly invasive and metastatic B16-BL6 mouse melanoma cells, 
lead to a decrease in pulmonary metastasis, possibly related to the GM3 ganglioside 
decrease (Tokuyama et al., 1997). Within addition, highly metastatic mouse colon 
adenocarcinoma cells transfected with Neu2 showed a marked reduction in lung 
metastasis, invasion and cell motility, with concomitant decrease in sLex and GM3 levels. 
This was suggested to be related with changes in cell adhesion and/or cell motility 
(Sawada et al., 2002), pointing to desialylation of these and other molecules, as targets of 
sialidase, involvement in the suppression of metastasis. Furthermore, a human 
epidermoid carcinoma cell line transfected with Neu2 gene, showed reduced GM3 levels,  
and a concomitantly increased cell growth and tyrosine autophosphorylation of epidermal 
growth factor receptors (EGFR) at low EGF (epidermal growth factor)concentration levels 
(Meuillet et al., 1999). Moreover, human NEU2 overexpressing leukemic  cells presented 
marked decrease in anti-apoptotic factors Bcl-XL and Bcl-2, resulting in increased 
sensitivity to apoptotic stimuli (Tringali et al., 2007). NEU2 overexpression in the cells 
reduced gene expression and activity of Bcr-Abl, together with a decrease in Bcr-Abl 
dependent Src and Lyn kinase activity probably through desialylation of cytosolic 
glycoproteins. 
Neu3 is up-regulated in several types of human cancer, such as colon, renal, 
ovarian and prostate cancers. However, Neu3 down-regulation was also observed in 
acute lymphoblastic leukemia and associated to disease progression (Mandal et al., 
2010). NEU3 mRNA levels were found to be 3–100-fold increased in human colon 
cancers, compared with adjacent normal mucosa (Kakugawa et al., 2002). Furthermore, 
in renal cell carcinomas NEU3 mRNA levels were observed to be significantly increased 
(Ueno et al., 2006). In the case of prostate cancer, Neu3 is also up-regulated and it’s 
correlated with malignancy (Kawamura et al., 2012). Prostate cancer cells revealed a 
significant decrease in invasion and migration capacity after NEU3 knockdown in 
vitro.NEU3 activates molecules such as EGFR, FAK, ILK, Shc and integrin β4, frequently 
up-regulated in carcinogenesis, being possibly the reason for the development of a 
malignant phenotype. In addition, this sialidase was found to increase azoxymethane-
induced aberrant crypt foci formation in colon mucosa by suppression of apoptosis 
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possibly due to the activation of EGF signalling. NEU3 is thus involved in the regulation of 
transmembrane signalling at the cell surface through both modulation of gangliosides as 
the result of enzyme reactions and by interaction with other signal molecules, including 
caveolin-1, Rac-1, integrin β4, Grb-2 and EGFR (Miyagi et al., 2008).  
In what regardsNEU4 sialidase, its levels are markedly decreased in human colon 
cancer (Yamanami et al., 2007). In addition, human colon adenocarcinoma cell lines 
transfected with NEU4 showed increased apoptosis and decreased invasiveness capacity 
and cellular motility (Shiozaki et al., 2011). To elucidate the significance of NEU4 down-
regulation in colon cancer, sialyl-Lewis antigens, sLea and sLex, were investigated, and 
Neu4 was found to hydrolyze these antigens in vitro and decrease their cell surface levels 
farly more than the other sialidases (Shiozaki et al., 2011). 
These multiple features suggest that each type of sialidase may play a unique role 
according to its properties. The role of sialidases in cancer is probably closely related to 
the available substrate which poses several therapeutic implications. 
Sialylation and cancer 
A general increase in sialylation is often found in cell surface glycoproteins of 
malignant cells (Neufeld et al., 2001). Altered sialylation of glycolipids is also observed to 
be a ubiquitous phenotype (Achyuthan et al., 2001). In fact, tumour-associated antigens 
are often sialylated. 
Tn antigen is the precursor of the T antigen, also known as Core 1. The Tn antigen 
does not occur in abundance in normal cells and tissues of adult animals, however it can 
be detected in almost all kinds of carcinomas (Julien et al., 2001). Almost 90% of breast 
cancers express Tn antigen while it is scarcely detected in normal mammary tissue 
(Springer 1997). This antigen was found to be associated to with the Pathological 
Tumour-Node Metastasis (PTNM staging) tumour stage in Invasive Ductal Carcinoma of 
the breast (Wang et al., 1997). Tn antigen can be sialylated at the C6 position of GalNAc 
residue, resulting in the dissacharide Neu5Acα2-6GalNAc-R, sTn antigen (sialylated Tn 
antigen). sTn is suggested to have an important role in carcinogenesis. Its expression is 
rarely observed in normal tissues but highly expressed in most several carcinomas such 
as gastric (David et al., 1992); (Victorzon et al., 1996); (Baldus et al., 2000), colorectal 
(Itzkowitz et al., 1990), ovarian (Kobayashi et al., 1992), breast (Leivonen et al., 2001); 
(Yonezawa et al., 1992), and pancreatic (Kim et al., 2002). Thus, sTn has been 
associated with carcinoma aggressiveness and poor prognosis. 
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T antigen is an oncofetal glycan antigen. It is originated by a non-elongated form of 
Core 1. In normal epithelium, T antigen is masked by sialic acids, sulphates or by addition 
of other sugar chains to form branched and complex O-glycans (Springer 1984); (Hanisch 
et al., 1997). T antigen is a pancarcinoma antigen expressed in several types of cancer 
including breast (Kumar et al., 2005), colon (Baldus et al., 2000), bladder (Coon et al., 
1982), prostate (Janssen et al., 1996), liver (Cao et al., 1996), ovary (Ghazizadeh et al., 
1990) and stomach (Baldus et al., 2001), suggesting that changes in O-glycosylation 
provide some advantage to tumour development (Cazet et al., 2010). In vitro and in vivo 
studies show that T antigen facilitates metastases by binding galectin-3 which clusters 
MUC1 mucin at the cell surface thereby facilitating not only heterotypic adhesion between 
tumour and endothelial cells (Yu et al., 2007), but also homotypic adhesion between 
tumour cells essential for their survival in the blood stream (Zhao et al., 2010). Inhibition of 
galectin-3 with T antigen interaction was shown to reduce metastatic capacity (Glinskii et 
al., 2012). Core 1 was found to be mostly sialylated (sT antigen) in CMT, however its non-
sialylated form (T antigen) is expressed in tumour emboli (de Oliveira et al., 2011). 
The histoblood group Lewis antigens are found in most human epithelial tissues, 
where they are expressed at the terminal part of glycolipid and glycoprotein carbohydrate 
chains (Ravn et al., 2000). These antigens derive from the substitution of type 1 (Galβ1-
3GlcNAc) or type 2 (Galβ1-4GlcNAc) dissacharide sequences by fucose and sialic acid 
residues. Lea, Leb and sLea antigens derive from type 1 sequences, and Lex Ley and sLex 
antigens derive from type 2 (Cazet et al., 2010). In a normal context, sLex antigen 
expression is restricted to the immune system cells contributing to leukocyte function in 
the inflammatory response event via interaction with E-selectin expressed on endothelial 
cells (Cazet et al., 2010). On the other hand, sialyl-Lewis antigens are usually altered in 
cancer cells and show a good correlation with the metastatic risk in breast cancer 
patients. sLea and sLex antigens expression are found to be increased in breast cancer 
tissues, including primary breast carcinoma lesions (Renkonen et al., 1997). Levels of 
expression of sLex antigen are higher in breast cancer patients who had distant 
metastasis, when compared with patients presenting non-metastatic lesions (Matsuura et 
al., 1997); (Jeschke et al., 2005). 
Sialidase inhibition 
Oseltamivir phosphate (Tamiflu®, Roche) is an effective sialidase inhibitor, 
extensively used as an anti-influenza virus drug. It is a sialic acid analogue which interacts 
with the active sites of the influenza sialidase enzymes. Once in the liver, after oral 
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administration, oseltamivir is processed by esterases into the active form, oseltamivir 
carboxylate, which can inhibit the sialidase of influenza virus with high affinity (Varghese 
et al., 1998); (Wilson et al., 2003); (Zaccai et al., 2003). Other sialidase inhibitors are other 
oseltamivir carboxylate and zanamivir. 
Since this drug is targeted against viral sialidases, it is of the most importance to 
evaluate if it may also affect the activity of endogenous sialidases in humans. The four 
human sialidases are homologous of that of virus. For example, the structure of human 
cytosolic sialidase NEU2 showed to be similar to that of viral sialidases, containing exactly 
the same active site residues (Chavas et al., 2005). Some observations pointed to a 
possible inhibitory effect of oseltamivir on endogenous sialidases in rats and mice (Crain 
et al., 2004); (Izumi et al., 2007); (Moore et al., 2007); (Woronowicz et al., 2007). 
Oseltamivir and zanamivir are known to be effective in human sialidases at 1.2 and 0.05–
0.43 μM, respectively, by administration in patient’s plasma. Regarding viral sialidases, 
only low nanomolar concentrations are suficient to block viral sialidases activity, because 
viral and bacterial sialidases are 10 fold more sensitive than that of mammalian (Hata et 
al., 1998); (Chavas et al., 2010). In addition, 2-deoxy-2,3dehydro-N-acetylneuraminic acid 
(DANA), Neu5Ac2en, is a sialic acid analog and well-known inhibitor of almost all 
members of sialidases (Chavas et al., 2005). 
Thus, the role of oseltamivir in cancer cells has not been determined and 
information about its effects on cancer cells is scarce. It is necessary to perform studies in 
order to assess the role of oseltamivir in the biological behaviour of cells, and also its 
effect on living organisms. 
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Aims 
Malignant CMT is considered an excellent spontaneous model of mammary 
carcinogenesis, and comparative studies could greatly improve our understanding about 
key steps of the metastatic process in humans bringing mutual advantages in what 
concerns treatment (Soremno 2003) (Paoloni et al., 2008). 
The present study aimed to investigate the effects of a sialidase inhibitor, 
oseltamivir, in order to better understand whether sialidases play a putative role during 
mammary tumour progression. Thus, our specific objectives in order to evaluate the effect 
of sialidases inhibition in the biological behaviour and glycosylation pattern of CMT cell 
lines were: 
a) To assess the effect of sialidases inhibition, using oseltamivir, in cellular 
viability, proliferation capacity, migration and invasion capacity; 
b) To evaluate a possible glycoprofile alteration upon sialidase inhibition with 
oseltamivir. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31 
Cell lines and culture conditions 
Two distinct cell lines were used: 1) a benign cell line - CMA-07 - established at 
our laboratory from a primary complex adenoma excised from a 6-year-old female dog; 
and 2) a highly metastatic CMT cell line - CMT-U27 - established from a spontaneous 
canine mammary tumour, excised from a 14-year-old female dog through fine-needle 
aspiration, kindly provided by Professor Eva Héllmen, from Sweden (Hellmen 1992). The 
two cell lines were cultured at 37ºC in a humidified 5% CO2 incubator (Thermo Scientific, 
U.S.A.) and maintained in RPMI 1640 medium with Glutamax and 25 mM Hepes (Gibco 
Life Technologies, U.K.), supplemented with 10% of fetal bovine serum, FBS (Gibco Life 
Technologies, U.K.) and 1% Penicillin Streptomycin (10.000 units/ml penicillin: 10.000 
µg/ml streptomycin; Gibco Life Technologies, U.K.). 
Whenever necessary, re-plating of the cells was done by cell dethatching using 
tripsin, followed by a centrifugation (Eppendorf AG, Germany) at 37° C, 1200 rpm, for 5 
minutes. The resulting cell pellets were ressuspended in 3 ml of RPMI 1640 and cells 
were counted in a Newbauer’s chamber in a 1:2 dilution of cells in 0.4% trypan blue and 
cell count was done using the volume conversion factor for 1 mm3, which is 1x104. Cells 
were then prepared to be re-plated. 
Cell morphology analysis 
CMA07 and CMT-U27 cells were plated in a density of 1x104 cells per well, in 
triplicate. Three different oseltamivir doses were studied: 125 ng/mL, 1.25 µg/mL, and 
12.5 µg/mL oseltamivir, and PBS was used as control. Analysis of cell confluence and 
morphology were performed using a contrast inverted microscope during 7 days. 
Photographs were taken in days 1, 3 and 7 in two different magnifications (x4, x20). 
Cell proliferation assay 
CMA07 and CMT-U27 cells were cultured in 24 wells plates in triplicate for each condition: 
125 ng/ml, 1.25 µg/ml, 12.5 µg/ml and 125 µg/ml oseltamivir and PBS as control. Cell 
number was measured every day, in triplicate, during 7 days. Results obtained were 
recorded, the growth curves traced and statistical analysis was performed. 
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Cell viability assay 
Cell viability was determined using a commercial available kit CellTiter 96® AQueous 
One Solution reagent (Promega Corporation, U. S. A.), and performed according to 
manufacturer’s instructions. 
Briefly, cells were plated in triplicate in a 96 wells plate (Orange Scientific, 
Belgium), with a density of 5x103 cells per well. After cell adherence to the wells, 
oseltamivir was added in 125 ng/ml, 1.25 µg/ml, 12.5 µg/ml and 125 µg/ml oseltamivir 
concentrations, and PBS was used as control. Cell viability was measured by adding MTS 
tetrazolium reagent and absorbance was recorded at 490nm 2 hours after reagent 
addition. The assays were performed in triplicate or both CMA07 and CMT-U27 cell lines, 
during 48 hours, with time-points at 0, 2, 4, 6, 8, 10, 12, 24 and 48 hours. An additional 
control measurement was performed at time-point 0, in a culture well without cells. 
Wound-healing 
The wound-healing assay was performed in a time-lapse microscope, and wound 
image acquisition was done with 5 minutes intervals during 48 hours, using the program 
Axio Vision Release 4.8.2. and converted in video. 
Briefly, 20x104 cells were plated into a 24 wells culture plate (Falcon by Becton Dickinson 
Labware, U. S. A.) and after reaching high confluence an artificial "wound" was made with 
a pipette tip. Culture medium was replaced with the different oseltamivir doses: 125 ng/ml, 
1.25 µg/mL and 12.5 µg/ml oseltamivir and PBS as control. The migration was evaluated 
considering the “healing capacity” of cells during 48 hours. 
Matrigel Invasion Assay 
A matrigel invasion assay was performed to evaluate the invasive capacity of 
CMT-U27 cells. Briefly, inserts were re-hydrated with RPMI 1640 and maintained for 1 
hour at 37º in a humidified 5% CO2 incubator (Thermo Scientific, U.S.A.) to complete the 
hydration process. After insert rehydration, 1x105 cells were seeded on Matrigel-coated 
chambers in the presence of different oseltamivir doses (125 ng/ml, 1.25 µg/ml, 12.5 
µg/ml oseltamivir), and PBS as control, and cultured during 6 hours. After that, the content 
of each insert was removed and washed twice with PBS. Then, invasive cells were fixed 
with cold methanol for 20 minutes. After fixation, inserts were transferred to slides 
(Industrial Quality, Germany) and mounted with Vectashield mounting medium with DAPI 
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(Vector Laboratories, U.S.A.). Cell invading capacity was measured by counting the 
number of cells that passed through the Matrigel-coated filter. 
Fluorescence 
Cells were cultured in glass coverslips in 24 wells culture plates, and the culture 
medium was supplemented with 125 ng/ml, 1.25 µg/ml and 12.5 µg/ml oseltamivir and 
PBS as control, during 24 hours. After 24 hours of treatment, cells were washed with PBS 
and fixed with cold methanol for 20 minutes. Following methanol fixation, cells were re-
hydrated with PBS and then blocked with 10% BSA for 20 min. BSA was replaced with 
plant lectins SNA (Biotinylated Ederberry bark lectin, B-1305, Vector Laboratories, 
U.S.A.), MAL I (Biotinylated Maackia amurensis lectin I, B-1315, Vector Laboratories, 
U.S.A.), and MAL II (Biotinylated Maackia amurensis lectin II, B-1265, Vector 
Laboratories, U.S.A.) 1:300 diluted in PBS, incubated for 1 hour, at room temperature. For 
galectin-3-ligands fluorescence, BSA was replaced with biotinylated galectin-3 1:100 
diluted in PBS, and slides were incubated for 1 hour, at room temperature. After two 
washes with PBS, Streptavidin FITC-conjugated was incubated for 1 hour at room 
temperature in a 1:1000 dilution in PBS, protected from the light. For galectin-3 
fluorescence, BSA was replaced with anti-gal-3 antibody, 1:100 diluted in PBS, and slides 
were incubated overnight, at 4ºC. After two washes with PBS, slides were incubated with 
FITC-conjugated anti-rat secondary antibody diluted 1:200 in 5% BSA for 1 hour, 
protected from light, at room temperature.  
After two washes with PBS, slides were incubated for 10 minutes with DAPI 
(Sigma-Aldrich, U.S.A.) in PBS and slides were mounted in Vectashield mounting medium 
for fluorescence (Vector Laboratories, U.S.A.). Slides were analysed and images were 
taken in a Carl Zeiss fluorescent microscope (Carl Zeiss Microscopy, Germany). 
Western Blot analysis 
Cells from CMA07 and CMT-U27 cell lines were grown to confluence in 6 well-
plates. Then, oseltamivir was added (125 ng/ml, 1.25 µg/ml and 12.5 µg/ml oseltamivir), 
and cells were incubated for 24 hours. Then, cells were washed three times with PBS, 
and 200µl of a pre-prepared mixture of 1000µl of RIPA lysis buffer (50 mM Tris HCl, pH 8; 
150 mM NaCl; 1% NP-40; 0,5% sodium desoxicolate; 0,1% SDS) containing 40µl of 
complete protease inhibitor cocktail (Roche, Switzerland), 10µl of PMSF (phenylmethyl 
sulfonyl fluoride), and 10µl Na3VO4 (sodium orthovanadate) were added to each well. 
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After 10 minutes incubation, cells were scrapped, collected to tubes and centrifuged 
(Eppendorf AG, Germany) at 13000 rpm, for 10 minutes, at 4°C. After centrifugation, 
supernatants were collected and protein amount was quantified using the biocinchoninic 
acid method, Pierce™ BCA Protein Assay Kit (Pierce/ Thermo Scientific, U.S.A.), 
according to the manufacturer’s instructions. 
The total extracts were boiled for 5 min at 95°C in Laemmli sampling buffer, and 
runned in 10% SDS-PAGE. After electrophoresis, gels were transferred to a nitrocellulose 
membrane (Amersham Biosciences/GE Healthcare Life Sciences, U.K.) and incubated 
with lectins: Biotinylated Maackia amurensis lectin I (B-1315, Vector Laboratories, U.S.A.), 
Biotinylated Maackia amurensis lectin II (B-1265, Vector Laboratories, U.S.A.) and 
Biotinylated Ederberry bark lectin, SNA (B-1305, Vector Laboratories, U.S.A.) diluted 
1:500 in 5% BSA (Sigma-Aldrich, U.S.A.) in 1x PBS with 0.05% Tween-20 (Sigma-Aldrich, 
U.S.A.). After lectins incubation, three washes with PBS 0,05% Tween-20 were performed 
and membranes were incubated with avidin-biotin complex kit (Vectastain ABC kit 
Standard, Vector Laboratories, U.S.A.) for 1 hour at room temperature. For galectin-3-
ligand analysis, membranes were incubated with galectin-3 biotinylated 1:200 diluted. 
After three washes with PBS 0,05% Tween-20 were performed, membranes were 
incubated with avidin-biotin complex kit for 1 hour at room temperature. For galectin-3 
analysis membranes were incubated with anti-galectin-3 antibody 1:200 diluted 
(eBioscience, San Diego, CA) followed by HRP-conjugated anti-rat secondary antibody for 
1 hour incubation. Analysis were done by chemiluminescence using the ECL Western 
blotting detection reagent and films (both from GE Healthcare, U.K.). Western blot for 
actin diluted 1:4000 (Santa Cruz Biotechnology) was used as loading control. 
Statistical analysis 
Whenever adequate, the results were presented as mean ± standard deviation. 
Statistical analysis was performed using One Way ANOVA (Analysis of variance) test and 
for multiple comparisons Dunnett and Tukey’s tests with p<0,05 as the level of 
significance, in GraphPad Prism 5.02 version. 
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CMT cell morphology assessment in the absence and presence of 
oseltamivir 
Cell morphology assay was performed in CMA07 and CMT-U27 cell lines during 7 
days in order to determine if oseltamivir leads to morphologic alterations of cells. Different 
concentrations of oseltamivir were tested, 125 ng/mL, 1.25 µg/mL, 12.5 µg/mL, and PBS 
was used as control. Cell morphology was observed in an inverted microscope in days 1, 
3 and 7, and photographs were taken. 
No differences in cell clustering were observed in both CMA 07 and CMT- U27 cells in the 
different doses of oseltamivir, when compared with control cells. CMA07 and CMT-U27 
cell lines showed no differences in cell morphology for both cell lines with the different 
oseltamivir doses, when compared to non-treated cells (Figure 1). 
 
 
Figure 1. Evaluation of CMA07 and CMT-U27 cell morphology upon oseltamivir treatment. Morphology 
of cells was evaluated after oseltamivir addition. Compared with control cells (A, I respectively, x4 
magnification), no differences in cell clustering were observed in both CMA 07 (B – D, x4 magnification) and 
CMT- U27 cells (J – L, x4 magnification) in the different doses of oseltamivir. Compared with non-treated cells 
(E, M x20 magnification), no differences were observed in both CMA07 (F-H, x20 magnification) and CMT-
U27 cells (N-P, x20 magnification) in the different doses of oseltamivir. 
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In day 3, CMA07 cells treated with 1.25 and 12.5 μg/mL oseltamivir presented less 
cell clustering, compared with non-treated and 125 ng/mL oseltamivir treated cells. 
Concerning CMT-U27 cells treated with 12.5 ng/mL oseltamivir, less cell clustering was 
observed, compared with non-treated, 125 ng/mL oseltamivir, and 1.25 ng/mL oseltamivir 
treated cells. 
CMA07 cells showed no alterations concerning cell morphology in the different 
oseltamivir doses, when compared to non-treated cells. However, CMT-U27 cells treated 
with 12.5 µg/mL oseltamivir present larger and irregular cytoplasm and protrusions, when 
compared to non-treated cells (Figure 2). 
 
 
Figure 2. Evaluation of CMA07 and CMT-U27 cell morphology three days after oseltamivir treatment. 
After three days of oseltamivir treatment, cell morphology was evaluated. Compared with non-treated and 125 
ng/mL oseltamivir treated cells (A, B, x4 magnification),CMA07 cells treated with 1.25 and 12.5 μg/mL 
oseltamivir (C, D, x4 magnification) presented less cell clustering. Compared with non-treated, 125 ng/mL 
oseltamivir, and 1.25 ng/mL oseltamivir treated cells (I - K, x4 magnification), CMT-U27 cells treated with 12.5 
ng/mL oseltamivir (L, x4 magnification) showed less cell clustering. Compared with non-treated cells (E, x20 
magnification), CMA07 cells treated with oseltamivir (F - H, x20 magnification) showed larger and irregular 
cytoplasm, and protrusions. Compared with non-treated cells (M, x20 magnification), CMT-U27 cells treated 
with 12.5 μg/mL oseltamivir (P, x20 magnification) showed larger and irregular cytoplasm, and protrusions. 
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In day 7, no differences in cell clustering were observed in both CMA 07 and CMT- 
U27 cells in the different doses of oseltamivir, when compared with control cells. 
Differences in CMA07 cell morphology were observed in both 125 ng/mL and 12.5 µg/mL 
oseltamivir doses, presenting more round and shiny cells, when compared to non-treated 
cells. Concerning CMT-U27 cell line, no differences were observed in cell morphology in 
the different oseltamivir doses, when compared with non-treated cells (Figure 3). 
 
 
Figure 3. Evaluation of CMA07 and CMT-U27 cell morphology seven days after oseltamivir treatment. 
Compared with control cells (A and I respectively, x4 magnification), no differences in cell clustering were 
observed in both CMA 07 (B – D, x4 magnification) and CMT- U27 cells (J – L, x4 magnification) in the 
different doses of oseltamivir. After seven days of oseltamivir treatment, compared to non-treated cells (E, x20 
magnification), differences in CMA07 cell morphology where observed in both 125 ng/mL (F, x20 
magnification) and 12.5 μg/mL oseltamivir treatment (H, x20 magnification), presenting more round and shiny 
cells. Compared with non-treated cells (M, x20 magnification), CMT-U27 cells treated with treated with 
oseltamivir (N-P, x20 magnification) showed no differences in cell morphology. 
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Cell proliferation assay in CMT cell lines in the absence and presence 
of oseltamivir 
In this study, cell proliferation assay was performed both with CMA07 and CMT-
U27 cell lines, using oseltamivir in order to determine if cell proliferation is affected by its 
presence. Oseltamivir was tested in different doses (125 ng/mL, 1.25 µg/mL, 12.5 µg/ml 
and 125 µg/mL oseltamivir) and PBS was added to the non-treated cells group. Cell 
growth was monitored during 7 days by counting cells every day (Figure 4). 
Proliferation rates of CMA07 and CMT-U27 cell lines were not significantly affected 
by treatment with different oseltamivir doses, when compared to the proliferation curve of 
non-treated cells. However, an exception was observed for the highest dose tested, 125 
µg/mL of oseltamivir, which seemed to impair CMA07 cell growth, though with no 
statistical significance was found when compared to non-treated cells. 
 
Figure 4. In vitro proliferation analysis of CMA07 and CMT-U27 cell lines upon oseltamivir treatment. 
Cells were cultured in 24-well dishes in the presence of different oseltamivir doses, and cell growth was 
monitored during 7 days by counting cells every single day. CMA07 and CMT-U27 cell lines in the presence of 
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different doses of oseltamivir did not present significantly different proliferation rates when compared with non-
treated cells. The highest dose administered, 125 μg/mL oseltamivir, impairs CMA07 cell growth (although 
with no statistical significant difference, ns p = 0.3492). 
 
Cell viability assay of CMT cell lines in the absence and presence of 
oseltamivir 
Cell viability assay performed with the CellTiter 96® AQueous One Solution reagent 
(Promega Corporation, U. S. A.) is a colorimetric method for determining the number of 
viable cells in proliferation or cytotoxicity assays. The MTS tetrazolium compound in the 
reagent is bioreduced by cells into a colored formazan product and analysed after 
recording the absorbance at 490nm. The quantity of formazan product as measured by 
the absorbance at 490nm is directly proportional to the number of living cells in culture. 
With the purpose of evaluate the effect of oseltamivir treatment in both CMA07 and 
CMT-U27 cells’ viability, CellTiter 96® AQueous One Solution Cell Proliferation Assay 
was performed in both CMA 07 and CMT- U27 cell lines, during 48 hours, with time-points 
at 0, 2, 4, 6, 8, 10, 12, 24 and 48 hours (Figure 5). 
For CMA07 and CMT-U27 cell lines treated with 125 ng/mL, 1.25 µg/mL and 12.5 
µg/mL oseltamivir doses, no significant differences (ns p>0.05) were observed in cells’ 
viability, when compared to non-treated cells. However, the highest tested dose, 125 
µg/ml oseltamivir, severely impaired cell viability both in CMA07, ***p=0.0005, and CMT-
U27, ****p<0.0001, cell lines, since the number of viable cells decreased over time. For 
this reason, this dose was excluded from the further studies. 
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Figure 5. Evaluation of CMA07 and CMT-U27 cell viability upon oseltamivir treatment. Cells were 
cultured in 96-well plates in the presence of the different oseltamivir doses, and cell viability was monitored in 
a time course manner during 48 hours. Cell viability from CMA07 and CMT-U27 cell lines was significantly 
affected by treatment with 125 μg/mL oseltamivir dose when compared to non-treated cells, which severely 
impairs CMA07 (***p=0.0005) and CMT-U27 (****p<0.0001) cell growth. 
 
 
 
 
 
 
 43 
CMT cell lines migration capacity evaluation by wound-healing in the 
absence and presence of oseltamivir 
Wound-healing assay is a simple and inexpensive method that mimics cell 
migration to close an artificial wound. In order to determine if oseltamivir treated cells from 
both CMA07 and CMT-U27 cell lines showed alterations in their migration rate, when 
compared to non-treated cells and between different oseltamivir doses, it was created an 
artificial "wound" in a cell monolayer. Results obtained by time-lapse acquisition allowed 
observing the cell migration of CMA07 and CMT-U27 cell lines during wound healing for 
40h. Oseltamivir was tested in different doses (125 ng/ml, 1.25 µg/ml, 12.5 µg/ml) and 
PBS was added to the non-treated cells group. 
Oseltamivir treated cells from both CMA07 and CMT-U27 cell lines showed evident 
alterations in their migration rates, when compared to non-treated cells and between 
doses. Regarding CMA07 cell line (Figure 6), it was observed that cells treated with 
125ng/mL and 1.25 µg/mL oseltamivir migrated in order to close the wound in a larger 
extent and moved faster, when compared to non-treated cells and cells treated with 12.5 
µg/mL oseltamivir. Concerning CMT-U27 cell line (Figure 7), it was also observed that 
cells migrated to close the wound in a dose-dependent manner. 
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Figure 6. Wound-healing assay in CMA07 cells treated with oseltamivir. Results obtained by time-lapse 
acquisition allowed the observation of cell migration of CMA07 cell line during wound healing for 40 hours. Cell 
migration was evaluated in each oseltamivir dose tested, and alterations were observed in the migration rate 
when compared to non-treated cells. CMA07 cells treated with 125ng/mL and 1.25 µg/mL oseltamivir migrated 
in order to close the wound in a larger extent and moved faster when compared to non-treated cells and cells 
treated with 12.5 µg/mL oseltamivir. 
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Figure 7. Wound-healing assay in CMT-U27 cells treated with oseltamivir. Results obtained by time-lapse 
acquisition allowed the observation of cell migration of CMT-U27 cell line during wound-healing for 40 hours. 
Cell migration was evaluated in each oseltamivir dose tested, and alterations in the migration rate were 
observed when compared to non-treated cells. It was observed that cells migrated to close the wound in a 
dose-dependent manner. 
 
Assessment of invasion capacity of CMT-U27 cell line in the absence 
and presence of oseltamivir 
The BD BioCoat™ Matrigel™ Invasion Chamber (BD Biosciences, U.S.A.) is 
useful to evaluate the capacity of malignant and normal cells to invade basement 
membranes. In addition, it also can be used to study the effect of specific drugs or altered 
protein expression on the invasive capacity of cells in vitro. The matrigel matrix works as a 
reconstituted basement membrane in vitro. The layer occludes the pores of the 
membrane, blocking non-invasive cells from migrating through the membrane. In contrast, 
invasive cells are able to detach and invade through the matrigel matrix and the 8 micron 
membrane pores. 
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CMT-U27 cell line is described to be a highly metastatic canine mammary tumour 
cell line (Hellmen 1992). Thus, the Matrigel invasion assay was performed using this cell 
line. CMT-U27 cell invasion capacity was evaluated by counting the number of invasive 
cells on Matrigel invasion chambers in the presence and absence of oseltamivir treatment 
(Figure 8). 
Cells treated with 125 ng/mL oseltamivir showed no significant differences in the 
invasion capacity when compared with non-treated cells (ns p<0.05). A significantly 
increase in cell invasion was observed in cells treated both with 1.25 µg/mL and 12.5 
µg/mL oseltamivir, compared to control cells (* p<0.05 1.25 µg/mL oseltamivir treated cells 
versus control cells; ** p<0.01 12.5 µg/mL oseltamivir treated cells versus control cells). 
Furthermore, significant differences in cell invasion capacity were also observed between 
different oseltamivir doses tested (**p<0.01 125 ng/mL oseltamivir versus 12.5 µg/mL 
oseltamivir; *p<0.05 1.25 µg/mL oseltamivir versus 12.5 µg/mL oseltamivir). 
 
 
 
Figure 8. In vitro evaluation of CMTU-27 invasive capacity upon oseltamivir treatment. Cell invasion was 
assessed on Matrigel chambers through 6 hours of oseltamivir treatment. Cells treated with 125 ng/mL 
oseltamivir show no significant differences in invasion capacity when compared to with non-treated cells (ns 
p>0.005). Cells with 1.25 µg/mL oseltamivir treatment present a significant increase in their invasive capacity 
when compared to non-treated cells (*p<0.05), as well as cells with 12.5 µg/mL oseltamivir treatment 
(**p<0.01). Differences in cell invasion capacity was also observed between the different oseltamivir 
treatments, indicating a dose-dependent invasion capacity (*p<0.05 1.25 µg/mL oseltamivir versus 12.5 µg/mL 
oseltamivir, and **p<0.01 125 ng/mL oseltamivir versus 12.5 µg/mL oseltamivir). 
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Evaluation of terminal α2-6 and 2-3 sialic acid structures expression in 
CMT cell lines in the absence and presence of oseltamivir 
In order to evaluate the effect of oseltamivir treatment in the glycosylation pattern 
of CMA07 and CMT-U27 cell lines, namely, alterations in terminal α2-3 and α2-6 sialic 
acid structures expression, fluorescence analysis were performed with SNA (Sambucus 
nigra agglutinin), MAL I (Maackia amurensis leukoagglutinin) and MAL II (Maackia 
amurensis hemagglutinin) plant lectins. 
Terminal α2-6 sialic acid structures expression in CMA07 and CMT U27 cell lines 
was assessed using the SNA plant lectin (Figure 9). CMA07 cells treated with oseltamivir 
showed an increased expression in terminal α2-6 sialic acids structures, when compared 
to non-treated cells. CMT-U27 cells treated with different doses of oseltamivir did not 
present an increased in the percentage of cells expressing α2-6 sialic acids structures, 
however cells presented a much more intense pattern of expression is displayed when 
compared to non-treated cells. 
 
 
 
Figure 9. Expression of terminal α2-6 sialic acids structures in CMA07 and CMT-U27 cell lines upon 
oseltamivir treatment, evaluated by SNA lectin labelling. Compared to non-treated cells (A, x20 
magnification), CMA07 cells treated with oseltamivir (B-D, x20 magnification), show an increased expression 
in terminal α2-6 sialic acids structures. Compared to non-treated cells (E, x20 magnification), CMT-U27 cells 
treated with different doses of oseltamivir (F-H, x20 magnification) did not present an increased in the 
percentage of cells expressing α2-6 sialic acids structures, however cells displays a much more intense 
pattern of expression. 
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Regarding Siaα2-3Galβ1-4GlcNAc terminal structures, their expression in CMA07 
and CMT-U27 cell lines was assessed by MAL I lectin labelling (Figure 10). CMA07 cells 
treated with 12.5 μg/mL oseltamivir showed an increased in Siaα2-3Galβ1-4GlcNAc 
structures, when compared to non-treated cells. CMT-U27 cells treated with oseltamivir in 
different doses, showed an increased in Siaα2-3Galβ1-4GlcNAc structures when 
compared to non-treated cells. 
 
 
Figure 10. Expression of Siaα2-3Galβ1-4GlcNAc  terminal structures in CMA07 and CMT-U27 cell lines 
upon oseltamivir treatment, assessed by MAL I lectin labelling. Compared to non-treated cells (A, x20 
magnification), CMA07 cells treated with 12.5 μg/mL oseltamivir (D, x20 magnification) show an increased in 
Siaα2-3Galβ1-4GlcNAc structures. Compared to non-treated cells (E, x20 magnification), CMT-U27 cells 
treated with oseltamivir in different doses (F-H, x20 magnification), show an increased in Siaα2-3Galβ1-
4GlcNAc structures. 
 
Concerning Siaα2-3Galβ1-3GlcNAc terminal structures, expression in CMA07 and 
CMT-U27 cell lines was accessed by MAL II lectin labelling (Figure 11). CMA07 cells 
treated with different doses of oseltamivir did not present alteration in Siaα2-3Galβ1-
3GlcNAc expression, when compared to non-treated cells. CMT-U27 cells treated with 
1.25 μg/mL oseltamivir showed increased expression of Siaα2-3Galβ1-3GlcNAc, when 
compared to non-treated cells. 
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Figure 11. Expression of Siaα2-3Galβ1-3GlcNAc terminal structures in CMA07 and CMT-U27 cell lines 
upon oseltamivir treatment, assessed by MAL II lectin labelling. Compared to non-treated cells (A, x20 
magnification), CMA07 cells treated with different doses of oseltamivir (B-D, x20 magnification) do not present 
alteration in Siaα2-3Galβ1-3GlcNAc expression. Compared to non-treated cells (E, x20 magnification), CMT-
U27 cells treated with 1.25 μg/mL oseltamivir (F, x20 magnification) show increased expression of Siaα2-
3Galβ1-3GlcNAc. 
 
Evaluation of galectin-3-ligands expression in CMT cell lines in the 
absence and presence of oseltamivir 
Fluorescence assay was performed in order to evaluate galectin-3-ligands 
expression in CMA07 and CMT-U27 cell lines treated with oseltamivir, when compared to 
non-treated cells (Figure 12). 
CMA07 cells treated with oseltamivir showed no differences in galectins-3-ligands 
expression, when compared with control cells. 
Treatment of CMT-U27 cells with 1.25 μg/mL and 12.5 μg/mL oseltamivir resulted 
in a decreased expression of galectin-3-ligands when compared to non-treated cells. 
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Figure 12. Evaluation of galectin-3 ligands expression in both CMA07 and CMT-U27 cell lines upon 
oseltamivir treatment. Compared to non-treated cells (A, x20 magnification), treatments of CMA07 cells (B-
D, x20 magnification) showed no differences in galectin-3-ligands expression. Compared to non-treated cells 
(E, x20 magnification), treatment of CMT-U27 cells with 1.25 μg/mL and 12.5 μg/mL oseltamivir (G,H, x20 
magnification), show a decreased in expression of galectin-3 ligands. 
 
Evaluation of galectin-3 expression in CMT cell lines in the absence 
and presence of oseltamivir 
Immunofluorescence assay was performed in order to evaluate galectin-3 
expression in CMA07 and CMT-U27 cell lines upon oseltamivir treatment, when compared 
to non-treated cells (Figure 13). 
Results showed that galectin-3 is increased in both CMA07 and CMT-U27 cells 
upon treatment with 1.25 μg/mL and 12.5 μg/mL oseltamivir, when compared to both non-
treated cells and to cells treated with 125 ng/mL oseltamivir. Moreover, differences in 
galectin-3 expression were also observed between the two cell lines, with more intense 
galectin-3 expression pattern in CMT-U27, when compared with CMA07. 
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Figure 13. Expression of galectin-3 in CMA07 and CMT-U27 cell lines upon oseltamivir treatment. 
Compared to both non-treated cells (A,E, x20 magnification) and to cells treated with 125ng/mL of oseltamivir 
(E,F, x20 magnification), there is increased expression of galectin-3 in both CMA07 (C-D, x20 magnification) 
and CMT-U27 cells (G-H, x20 magnification) upon treatment with 1.25 μg/mL and 12.5 μg/mL oseltamivir. 
Furthermore, galectin-3 expression pattern in CMT-U27 is more intense when compared with CMA07. 
 
Evaluation of terminal α2-6 and 2-3 sialic acid structures expression in 
proteins from total cell lysates of CMT cell lines in the absence and 
presence of oseltamivir  
Expression of terminal α2-6 and α2-3 sialylated structures were evaluated by lectin 
blot analysis with SNA, MAL I and MAL II lectins. The results demonstrated an increased 
expression of sialylated proteins upon oseltamivir treatment (Figure 14). 
Both CMA07 and CMT-U27 cells presented differences in the expression of 
terminal α2-6 and α2-3 sialic acid structures in some proteins upon oseltamivir treatment. 
These results demonstrated the effect of oseltamivir in sialidase inhibition, and 
consequent inhibition of sialic acid cleavage, since it was observed an increased α2-6 and 
α2-3 sialic acid terminal structures in cells treated with oseltamivir. 
The results from SNA lectin blot demonstrated an increase in the expression of 
terminal α2,6 sialic acid structures in proteins from CMT-U27 cells treated with oseltamivir 
(125 ng/mL, 1.25 µg/mL and 12.5 µg/mL oseltamivir) when compared to proteins from 
non-treated cells (PBS), especially in a molecular weight around 120 kDa. Regarding MAL 
I lectin blot, no differences were observed in α2,3 sialic acid structures in proteins from 
both CMA07 and CMT-U27 cells treated with oseltamivir (125 ng/mL, 1.25 µg/mL and 
12.5 µg/mL oseltamivir), when compared to proteins from non-treated cells (PBS). The 
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results from MAL II lectin blot demonstrated an increase in terminal α2,3 sialic acid 
structures expression in proteins from lysates of cells treated with 125 ng/mL, 1.25 µg/mL 
oseltamivir, in a molecular weight around 120 kDa, when compared to proteins from non-
treated cells (PBS) and cells treated with 12.5 µg/mL oseltamivir. 
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Figure 14. Western analysis of SNA, MAL I and MAL II lectins in proteins from total cell lysates of both 
CMA07 and CMT-U27 cell lines upon oseltamivir treatment. Expression of terminal sialylated structures 
were evaluated by western blot analysis with SNA (A), MAL I (B) and MAL II (C) plant lectins. The results from 
SNA lectin blot (A) demonstrated an increase in the expression of terminal α2,6 sialic acid structures in 
proteins from CMT-U27 cells treated with oseltamivir (125 ng/mL, 1.25 µg/mL and 12.5 µg/mL oseltamivir) 
when compared to proteins from non-treated cells (PBS), especially in a molecular weight around 120 kDa. 
Regarding MAL I lectin blot (B), no differences were observed in α2,3 sialic acid structures in proteins from 
both CMA07 and CMT-U27 cells treated with oseltamivir (125 ng/mL, 1.25 µg/mL and 12.5 µg/mL oseltamivir), 
when compared to proteins from non-treated cells (PBS). The results from MAL II lectin blot (C) CMT-U27 
cells demonstrated an increase in terminal α2,3 sialic acid structures expression in proteins from lysates of 
cells treated with 125 ng/mL, 1.25 µg/mL oseltamivir, in a molecular weight of about 120 kDa, when compared 
to proteins from lysate correspondent to non-treated cells (PBS) and cells treated with 12.5 µg/mL oseltamivir. 
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Evaluation of galectin-3-ligands expression in proteins from total cell 
lysates of CMT cell lines in the absence and presence of oseltamivir 
Proteins from CMA07 and CMT-U27 cell lines treated with oseltamivir were 
labelled with biotinylated galectin-3 in order to evaluate galectin-3-ligands expression in 
proteins from total cell lysates of both cell lines (Figure 15). 
Regarding galectin-3-ligands expression in proteins from CMA07 cell line treated 
with oseltamivir, no differences were observed for when compared to proteins from non-
treated cells (PBS). Concerning galectin-3-ligands expression in proteins from CMT-U27 
cell line treated with oseltamivir, we observed a decrease in galectin-3 ligands in proteins 
when compared to proteins from non-treated cells, especially at the molecular weight 
around 120 kDa. 
 
 
 
Figure 15. Western blot analysis of galectin-3-ligands in proteins from total cell lysates of both CMA07 
and CMT-U27, upon oseltamivir treatment. Expression of galectin-3-ligands was evaluated by western blot 
analysis with a biotinylated galectin-3. Regarding galectin-3-ligands expression in proteins from CMA07 cell 
line treated with oseltamivir, no differences were observed for when compared to proteins from non-treated 
cells (PBS). Concerning galectin-3-ligands expression in proteins from CMT-U27 cell line treated with 
oseltamivir, we observed a decrease in galectin-3 ligands in proteins when compared to proteins from non-
treated cells, principally at the molecular weight around 120 kDa. 
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Evaluation of galectin-3 expression in proteins from total cell lysates 
of CMT cell lines in the absence and presence of oseltamivir 
CMA07 cells treated with oseltamivir showed no differences in galectin-3 
expression, when compared to non-treated cells (Figure 16). CMT-U27 cells treated with 
1.25 µg/mL and 12.5 µg/mL oseltamivir treatments, showed increased galectin-3 
expression, when compared to non-treated cells. These results are in accordance with 
those observed for galectin-3 immunofluorescence. 
 
 
 
Figure 16. Western blot analysis of galectin-3 in proteins from total cell lysates of both CMA07 and 
CMT-U27, upon oseltamivir treatment. CMA07 cells treated with oseltamivir, showed no differences in 
galectin-3 expression, when compared to non-treated cells. CMT-U27 cells treated with 1.25 µg/mL and 12.5 
µg/mL oseltamivir treatments, showed increased galectin-3 expression, when compared to non-treated cells. 
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Discussion 
Canine mammary tumours (CMT) affect female dogs with higher incidence 
between 10 and 11 years of age (Johnston, 1993), being the second most common type 
of canine neoplasia, 25-50% of all diagnosed cases (Moulton, 1990). CMT present many 
similarities with human breast cancer, namely, histological appearance, tumour genetics, 
molecular targets, biological behaviour and response to conventional therapies (Paoloni et 
al., 2008). However, CMT show a higher incidence compared to humans, about 3 folds, 
and a shorter disease time course of approximately 2 years (Sorenmo 2003). Regarding 
breast cancer, it is one of the most prevalent cancers worldwide, being the leading cause 
of cancer-related death in women (Ferlay et al., 2010). Hence, the study of CMT as an 
animal model of human breast cancer could greatly improve our knowledge about the 
metastatic process in humans and bring mutual advantages for cancer treatment (Paoloni 
et al., 2008). 
Glycoconjugates present in the cell surface play important roles in a variety of 
biological functions, and alterations in glycosylation are considered a hallmark during 
carcinogenesis. These alterations lead to the expression of tumour-associated 
carbohydrate antigens (TACA) on glycoproteins and glycolipids which decorate the cell 
surfaces (Reis et al., 2010). T antigen, its sialylated form sT, Tn antigen and sTn, and 
sialyl Lewis antigens: sLex and sLea are among these TACA (Baldus et al., 2004); (Cazet 
et al., 2010). Geseneral sialylation increaare commonly found in glycans of carcinoma 
cells, being associated with tumour grade, invasion, metastasis and poor prognosis of 
patients (Cazet et al., 2010). Removal of α-glycosidically linked sialic acid residues form 
carbohydrate groups of glycoproteins and glycolipids is catalized by sialidases. This event 
affects the conformation of glycoproteins (Yogeeswaran et al., 1981).  
In the present work we took advantage of a well-known sialidase inhibitor, 
oseltamivir, to assess its effect both on the biological behaviour and glycosylation pattern 
of canine mammary tumour cells. 
Breast cancer cells express shorter O-glycans due to blocking of further extension by 
premature sialylation (Cazet et al., 2010). Sialidases are glycosidases which catalyse the 
removal of α-glycosidically linked sialic acid residues from carbohydrate groups of 
glycoproteins and glycolipids (Miyagi et al., 2012). In order to assess the effect of 
sialidases inhibition by treatment with oseltamivir in the biological behaviour of CMA07 
and CMT-U27 cell lines, we proceeded to several in vitro studies. We performed a cell 
morphology assay during 7 days and it was observed that treatment with oseltamivir 
affected cell morphology. At day 3, CMT-U27 cells treated with 12.5 µg/mL oseltamivir 
showed larger and irregular cytoplasm, in contrast with small and round control cells. And 
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at day 7 these differences were no longer visible. Regarding CMA07 cells, at day 7 cells 
treated with 125 ng/ml and 12.5 µg/mL oseltamivir depicted a more round morphology, 
comparing with control cells. Some studies evaluated the effect of sialidases in cancer cell 
morphology. In accordance with our observations, HEK293 cell line transfected with TLR4 
gene when treated with oseltamivir and LPS (TLR4 ligand lipopolysaccharide) depicted a 
circular morphology compared with controls (Amith et al., 2010). On the other hand, in a 
sialidase overexpressing cell model, Kato et al. and Sawada et al. did not find any 
alterations in cell morphology (Kato et al., 2001, Sawada et al., 2002). Furthermore, we 
evaluated cell proliferation and cell viability both in CMA07 and CMT-U27 cell lines. Cell 
proliferation and viability were not significantly affected with oseltamivir treatment. This 
result lead us to assume that 1) alterations in sialic acid content at cell surface by 
sialidase inhibition with oseltamivir treatment do not affect cell cycle machinery, or 2) 
oseltamivir treated cells acquire an adaptive capacity, thereby maintaining a normal 
proliferation rate and viability. However, the highest oseltamivir dose tested was an 
exception to the general results since it impaired cell proliferation and viability of both cell 
lines. Nevertheless, it seems that this dose was cytotoxic since we observed more death 
cells in the culture medium, but without performing further cell death assays, we cannot 
conclude about its cytotoxicity. Some studies evaluated the influence of sialidases in 
tumour growth. Kato el al., reported that overexpression of sialidase markedly reduced 
cell growth of murine melanoma cells both in vitro (by MTT assay) and in vivo (Kato et al., 
2001). In addition, Fluorinated sialic acid analogue (P-3Fax-Neu5Ac), a highly potent 
inhibitor of sialylation, blocked sialylation in murine melanoma B16F10 cells and reduced 
their growth in vivo (Bull et al., 2013). 
The metastatic process is the main cause of tumour-related death (Chambers et 
al., 2002). Distant metastases occurrence is a complex process dependent on several 
crucial anti/pro-adhesive steps among which detachment of tumour cells from primary 
sites, by loss of homotypic and heterotypic adhesion and homotypic aggregation of 
vessel-invading tumour cells is required for their survival in the blood stream (Orr et al., 
2001). Also, increased sialylation has been highly associated with tumour invasion (Cazet 
et al., 2010); (Gomes et al., 2013). Taking these findings into consideration, we decided to 
perform in vitro wound-healing and Matrigel invasion assays, in order to determine if 
oseltamivir treatment, and consequent increase in terminal sialic acid structures, would 
affect the capacity of CMT cells to invade and migrate. Results obtained by time-lapse 
acquisition allowed the observation of cell migration in both cell lines during wound 
healing for 40 hours. Cell migration was evaluated for each oseltamivir dose tested, and 
both cell lines showed evident alterations in migration rate, when compared to non-treated 
cells. Regarding CMA07 cell line, cells treated with 125ng/mL and 1.25 µg/mL oseltamivir 
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migrated in order to close the wound in a larger extent and moved faster, when compared 
to non-treated cells and cells treated with 12.5 µg/mL oseltamivir. In addition, in CMT-U27 
cell line, it was clearly observed that cells migrated to close the wound in a dose-
dependent manner. These observations suggest that the increase in terminal sialic acid 
structures, due to inhibition of sialidases by oseltamivir treatment, promoted increased cell 
migration, resulting in a higher ability to close the wound. These results are in agreement 
with some other reports that showed the importance of sialylated structures for cancer 
cells migration by wound healing experiments. In particularly, migration ability of human 
pancreatic carcinoma SW1990 cells treated with 1,3,4-O-Bu3 ManNAc, analog precursor 
for sialic acid biosynthesis, was evaluated by wound-healing assay and showed increased 
migration capacity in surface coated with fibronectin and collagen type (Almaraz et al., 
2012). In addition, B16F10 cancer cells treated with P-3Fax-Neu5Ac, which blocked 
sialylation, exhibited diminished migratory capacity (Bull et al., 2013). The results are in 
accordance with our observations, since the increase in sialylation increased migration 
capacity of cells. Concerning the results on Matrigel invasion assay, differences were 
observed in cell invasion capacity of CMT-U27 cells in a dose-dependent manner. The 
results evidenced the importance of sialic acid contents in cell invasive capacity. The 
association between sialylation and invasion have been claimed for many years. For 
instance, the expression of sialyl-Lewis antigens in breast cancer patients as been 
described as weak in carcinoma in situ, moderate in invasive carcinomas without 
metastases and high in primary carcinoma with lymph node metastases, showing a good 
correlation with the metastatic risk (Jeschke et al., 2005). In agreement with our results, 
invasion capacity of sialidase overexpressing colon carcinoma cells showed an inhibition 
of invasiveness around 30 to 40% (Sawada et al., 2002). Also, highly metastatic NL17 
mouse melanoma cell line overexpressing sialidase showed a marked suppression of 
pulmonary metastasis (Sawada et al., 1998). In addition, experimental pulmonary 
metastasis of a mouse colon adenocarcinoma cell line was inhibited by a sialyltransferase 
inhibitor, KI-8110 (Kijima-Suda et al., 1986); (Kijima-Suda et al., 1988). These results 
reinforce our observations that invasion capacity is enhanced by increase in sialylation. 
Our group has reported that sialylation is a predominant type of glycosylation in 
CMT (Pinho et al., 2009). Sialyl-Lewis antigens such as sLex, sLea and sTn are TACA 
normally found in breast cancer (Narita et al., 1993); (Soares et al., 1996). Normal breast 
tissue commonly expresses Lex, mainly in the apical part of cell ducts, together with 
MUC1 (Croce et al., 2007). On the contrary to unsyalylated structures, sLea and sLex 
expression is found to be increased in breast cancer tissues, including primary breast 
carcinoma lesions (Renkonen et al., 1997) (Julien et al., 2001). Tn antigen can be 
sialylated resulting in the synthesis of the disaccharide Neu5Acα2-6GalNAc-R, sTn, which 
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is absent in normal healthy tissues but detected in almost all kinds of carcinomas. In order 
to verify if inhibition of sialidases by oseltamivir can caused an increase in sialic acid 
contents and consequently affected cell glycosylation pattern, we performed fluorescence 
analysis of both CMA07 and CMT-U27 cell lines with plant lectins SNA (Sambucus nigra 
agglutinin), MAL I (Maackia amurensis leukoagglutinin) and MAL II (Maackia amurensis 
hemagglutinin). SNA is used to recognize specifically terminal α2-6 sialic acids structures. 
MAL I recognize not only terminal sialic acids α2-3 linked to galactose, but preferably 
Siaα2-3Galβ1-4GlcNAc structures. MAL II recognize preferably O-linked disialylated 
tetrassacharides Siaα2-3Galβ1-3(Neu5Ac α2-6)GlcNAc. Both cell lines showed an 
increase in α2-6 and α2-3 terminal sialylated structures upon treatment with oseltamivir. 
This result demonstrated that oseltamivir functions as a sialidase inhibitor in our cell line 
models, and confirms that inhibition of sialidases leads to an increase in sialic acid 
structures. It is described  that increased β 1,6-branching, that leads to increases in sLex 
or sLea antigens, or a general increase in sialylation are commonly observed in N-linked 
and O-linked glycans in carcinoma cells and are associated with grade, invasion, 
metastasis and poor prognosis (Cazet et al., 2010). In our study, and according to the 
recognition specificity of the different plant lectins used, the results suggested that we 
have an increase in sialylated structures, possibly sLex and sLea as well as sTn. In 
addition, and as described previously, we also observed that highly metastatic CMT-U27 
cell line showed increased capacity to invade Matrigel invasion chambers in a dose-
dependent manner when treated with oseltamivir. These results are in line with previous 
reported ones that showed that expression of sialyl-Lewis antigens is weak in carcinoma 
in situ, is moderate in invasive carcinomas without metastases and is high in primary 
carcinoma with lymph node metastases, showing a good correlation with the metastatic 
risk in breast cancer patients (Jeschke et al., 2005). Furthermore, levels of expression of 
sLex are higher in patients who had distant metastasis compared with patients presenting 
non-metastatic cancers (Matsuura et al., 1997).Regarding sTn antigen expression, it has 
been associated with carcinoma aggressiveness and poor prognosis, being highly 
expressed in most gastric (Baldus et al., 2000); (David et al., 1992); (Victorzon et al., 
1996), colorectal (Itzkowitz et al., 1990), ovarian (Kobayashi et al., 1992), breast 
(Yonezawa et al., 1992); (Leivonen et al., 2001), and pancreatic (Kim et al., 2002) 
carcinomas. 
MUC1 is a highly sialylated glycoprotein and a natural ligand of galectin-3 in 
human cancer cells, and usually its increased expression is associated with high 
metastatic potential and poor prognosis (Bresalier et al., 1991); (Nakamori et al., 1994). 
Cancer associated MUC1 expression has increased short oligosaccharides such as Tn, 
sTn, and T antigens (Lloyd et al., 1996). In our study, we performed fluorescence assay in 
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order to assess the presence of galectin-3-ligands both in CMA07 and CMT-U27 cell lines 
upon treatment with oseltamivir. Results obtained showed a decrease in galectin-3 ligands 
expression in CMT-U27 cells treated with 1.25 μg/mL and 12.5 μg/mL oseltamivir. 
Galectin-3 recognition was fund to be particularly impaired in a molecular weight which 
corresponds to that of MUC1. The results are in accordance with what was expected in 
which increased terminal sialic acid structures, as a consequence of sialidase inhibition by 
oseltamivir treatment, mask the common recognition structures of galectin-3. Our 
observations are in accordance with Powell et al. who reported that presence of sialic acid 
mask carbohydrate ligands of galectin-3 (Powell et al., 1987). de Oliveira JT et al., 
suggested that loss of galectin-3 and sialylation-related masking of its ligands is crucial in 
regulating adhesive/de-adhesive events in the progression and invasive capacity of 
metastatic CMT (de Oliveira et al., 2011). The presence of sialic acid can inhibit cell-cell 
interactions by masking carbohydrate ligands blocking receptor recognition (Powell et al., 
1987). This data is confirmed by our results in which highly metastatic CMT cells 
expressing increased terminal sialylated structures due to oseltamivir treatment, present 
decreased galectin-3-ligand expression, and a more aggressive phenotype as well as and 
an increased invasion capacity. Galectin-3 expression levels are increased in a variety of 
primary tumours (Liu et al., 2005). It is up-regulated in gastric, liver and thyroid cancer, 
compared to normal tissues. However, its downregulation was also described in some 
carcinomas such as the case of prostate cancer (Ellerhorst et al., 1999), ovarian cancer 
(van den Brule et al., 1994), colon cancer (Lotz et al., 1993), head and neck squamous 
cell carcinoma (Choufani et al., 1999), and breast (Castronovo et al., 1996) cancers. 
Cancer patients with metastatic dissemination have circulating galectin-3 concentrations 
markedly increased than those with localized tumours (Iurisci et al., 2000); (Vereecken et 
al., 2006); (Saussez et al., 2008). In order to assess galectin-3 expression, we performed 
immunofluorescence both in CMA07 and CMT-U27 cells upon treatment with oseltamivir. 
Results showed that galectin-3 expression is increased in both cell lines treated with 1.25 
μg/mL and 12.5 μg/mL oseltamivir. In addition, highly metastatic CMT-U27 cell line 
presented increased galectin-3 expression when compared to benign CMA07 cell line. 
Since protein glycosylation has been reported as important in the process of 
galectin3-protein interactions and also invasion, we decided to analyse the glycosylation 
pattern of glycoproteins in cell lysates of both CMA07 and CMT-U27 cell lines upon 
oseltamivir treatment. We assessed the expression of terminal sialylated structures by 
lectin blot analysis using plant lectins SNA, MAL I and MAL II. Interestingly, the results 
from lectin blot analysis with SNA lectin demonstrated an increase in terminal α2,6 sialic 
acid structures expression in proteins from CMT-U27 cells upon oseltamivir treatment. At 
least a very distinct glycosylation pattern was observed at the molecular weight of 120 
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kDa. Regarding the results of western blot analysis with MAL I and MAL II lectins, 
differences in the terminal α2,3 sialic acid structures were observed in few proteins from 
MAL II blot in CMT-U27 cells treated with oseltamivir. Apparently, MAL II showed 
increased protein recognition in the same molecular weight of proteins that had increased 
terminal α2,6 sialic acid structures in SNA blot. In addition, and regarding galectin-3-
ligands expression in proteins from CMT-U27 cells upon oseltamivir treatment, it was 
observed a decrease in galectin-3-ligands in proteins in a molecular weight around 120 
kDa. This observation strengthened the result of the western blot analysis with SNA lectin 
that demonstrated an increase in terminal α2,6 sialic acid structures expression in proteins 
from CMT-U27 cells treated with oseltamivir (125 ng/mL, 1.25 µg/mL and 12.5 µg/mL 
oseltamivir), more specifically, in a molecular weight a around 120 kDa. We conclude that, 
when we have increase in terminal α 2,6 sialic acid structures, galectin-3-ligands 
decrease, suggesting a masking of these ligands by α2,6 sialylated structures. This 
observation was reinforced by our fluorescence results where we observed a decrease in 
galectin-3-ligands in CMT-U27 cells treated with 1.25 μg/mL and 12.5 μg/mL oseltamivir 
with a concomitant increase expression of terminal α2,6 sialic acid structures. Regarding 
galectin-3 expression in proteins from total cell lysates of CMT-U27 cells, upon treatment 
with oseltamivir we observed an increase in galectin-3 expression. This observation was 
strengthened by the immunofluorescence galectin-3 expression in CMT-U27 cell line 
showed an increase in galectin-3 when cells were treated with 1.25 μg/mL and 12.5 
μg/mL oseltamivir. 
In summary, these results lead us to highlight the role of sialylation during CMT 
progression, since upon oseltamivir treatment we observed an increase in sialylated 
structures accompanied by an increase in invasion capacity and migration of cells, which 
are common features of enhanced malignancy. Sialidase inhibition is possibly a bottom 
line for further studies and anti-cancer therapy. 
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The present study showed that oseltamivir plays an important role in the biological 
behaviour and in glycosylation pattern of CMT (canine mammary tumour) cell lines. 
Sialidases inhibition by treatment with oseltamivir demonstrated that they act on 
glycoproteins during mammary tumour progression since we found an increase in 
invasion capacity and also in migration of cells. Moreover, in what regards glycosylation 
pattern, highly malignant CMT-U27 cells treated with oseltamivir, showed an increase in 
sialylated structures, with concomitant decrease in galectin-3-ligands. These observations 
point to an important dynamic expression of sialidases in CMMT (canine mammary 
malignant tumour). Thus, the results of this study are of the utmost importance suggesting 
in what concerns about differential/dynamic expression and activity of sialidases in 
invading cells in CMMT, possibly involved in sialic acid capping and uncapping of glycans 
during tumour progression and invasion. 
These results indicate that the discovery of a powerful inhibitor capable of inhibit 
aberrant sialylation could potentially be used for anti-cancer therapy. 
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